AU2003209669A1 - Amorphous form of losartan potassium - Google Patents

Amorphous form of losartan potassium

Info

Publication number
AU2003209669A1
AU2003209669A1 AU2003209669A AU2003209669A AU2003209669A1 AU 2003209669 A1 AU2003209669 A1 AU 2003209669A1 AU 2003209669 A AU2003209669 A AU 2003209669A AU 2003209669 A AU2003209669 A AU 2003209669A AU 2003209669 A1 AU2003209669 A1 AU 2003209669A1
Authority
AU
Australia
Prior art keywords
amorphous form
losartan potassium
losartan
potassium
amorphous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003209669A
Other languages
English (en)
Inventor
Reddy Attunuri Narasa
Reddy Bolla Narasa
Reddy Bandi Parthasaradhi
Reddy Rapolu Raji
Reddy Kura Rathnakar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hetero Drugs Ltd
Original Assignee
Hetero Drugs Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hetero Drugs Ltd filed Critical Hetero Drugs Ltd
Publication of AU2003209669A1 publication Critical patent/AU2003209669A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
AU2003209669A 2003-02-25 2003-02-25 Amorphous form of losartan potassium Abandoned AU2003209669A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2003/000037 WO2004076443A1 (fr) 2003-02-25 2003-02-25 Forme amorphe de potassium de losartan

Publications (1)

Publication Number Publication Date
AU2003209669A1 true AU2003209669A1 (en) 2004-09-17

Family

ID=32922922

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003209669A Abandoned AU2003209669A1 (en) 2003-02-25 2003-02-25 Amorphous form of losartan potassium

Country Status (2)

Country Link
AU (1) AU2003209669A1 (fr)
WO (1) WO2004076443A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060160871A1 (en) * 2004-12-07 2006-07-20 Nektar Therapeutics Stable non-crystalline formulation comprising losartan
WO2009004374A1 (fr) 2007-06-29 2009-01-08 Generics [Uk] Limited Procédé d'introduction d'une chaîne latérale hydroxyéthoxy dans le bosentan
NZ600010A (en) 2007-10-24 2013-11-29 Generics Uk Ltd Novel crystalline forms of bosentan, processes for their preparation and uses thereof
PT2245018T (pt) 2008-02-08 2017-12-05 Generics Uk Ltd Processo para preparar bosentano
US8975402B2 (en) 2008-11-03 2015-03-10 Generics [Uk] Limited HPLC method for the analysis of bosetan and related substances and use of these substances as reference standards and markers
CN104610232B (zh) * 2013-11-01 2019-09-20 深圳信立泰药业股份有限公司 阿利沙坦酯无定形及其制备方法及含所述无定形的药物组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5140037A (en) * 1990-03-20 1992-08-18 E. I. Du Pont De Nemours And Company Treatment of central nervous system disorders with imidazole angiotensin-ii receptor antagonists
ES2234451T1 (es) * 2001-11-14 2005-07-01 Teva Pharmaceutical Industries Ltd. Formas cristalinas y amorfas de losartan potasio y procedimiento para su preparacion.

Also Published As

Publication number Publication date
WO2004076443A1 (fr) 2004-09-10

Similar Documents

Publication Publication Date Title
AU2003904256A0 (en) Qubit readout
AU2003264337A1 (en) Monocycle
AU2003303648A1 (en) Novel 5-hydroxyindole-3-carboxylate derivatives
AU2003238671A1 (en) Novel crystalline forms of s-omeprazole magnesium
AU2003209669A1 (en) Amorphous form of losartan potassium
AU2003223106A1 (en) A novel amorphous form of valsartan
AU2003278422A1 (en) Amorphous form of losartan potassium
AU2003217438A1 (en) Novel crystalline forms of levetiracetam
GB0314149D0 (en) Novel amorphous forms
AU2003217509A1 (en) Germanium bio wallpaper
AU2005100106A4 (en) T&L ezyfume
AU2003264861A1 (en) Novel crystalline forms of celecoxib
AU2003238678A1 (en) Novel crystalline forms of sumatriptan succinate
AU2003238668A1 (en) Novel crystalline forms of valdecoxib
AU2003242984A1 (en) A novel crystalline form of irbesartan
AU2004900742A0 (en) A condom of sheath variation
AU2003248104A1 (en) Crystalline 6-n-pyridylmethylaminoindolocarbazoles
AU2004100592A4 (en) Ear hygiene tool
AU2004900525A0 (en) T & L Ezyfume
AU2004900166A0 (en) Archimedian Desalinator
AU2003901020A0 (en) Improvement to catalysators
AU2003905280A0 (en) Improvements relating to electrodewatering
AU2003269470A1 (en) A process for the synthesis of losartan potassium
AU2003901062A0 (en) Extension piece
AU2004905330A0 (en) Construction of amahs

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase